Bio Medica Laboratories IPO

IPO Details

• Open Date: 21 May 2026

• Close Date: 25 May 2026

• Minimum Investment: ₹2,78,000

• Lot Size: 1,000 shares

• Price Range: ₹132 to ₹139 per share

• Listing: NSE SME

• Issue Size: ₹52.43 Crore

• Listing Date: 29 May 2026

IPO Timeline

• Bidding Start: 21 May 2026

• Bidding Ends: 25 May 2026

• Allotment Finalisation: 26 May 2026

• Refund Initiation: 27 May 2026

• Demat Transfer: 27 May 2026

• Listing: 29 May 2026

About Bio Medica Laboratories Limited

Bio Medica Laboratories Limited, incorporated in August 2015, specializes in manufacturing pharmaceutical parenteral formulations, including liquid and dry-powder injectables for human and veterinary healthcare. The company offers ethical drugs, generic medicines, and OTC pharmaceutical products through a contract manufacturing B2B model. Its portfolio includes 58 liquid injectable products and 15 dry powder injectable products. With two manufacturing facilities in Indore, Madhya Pradesh, and certifications for GMP and GLP compliance, the company focuses on quality assurance, product diversification, and long-term client relationships.

Bio Medica Laboratories Limited IPO Overview

Bio Medica Laboratories Limited IPO is a bookbuilding issue worth ₹52.43 crore, comprising a fresh issue of ₹47.19 crore and an offer for sale of ₹5.24 crore. The IPO opens on 21 May 2026 and closes on 25 May 2026. The allotment is expected on 26 May 2026, while refunds and Demat transfers are scheduled for 27 May 2026. The company is set to list on NSE SME on 29 May 2026. The price band is fixed at ₹132 to ₹139 per share, with a lot size of 1,000 shares. Narnolia Financial Services Ltd. is the lead manager, and Skyline Financial Services Pvt. Ltd. is the registrar.

Bio Medica Laboratories Limited IPO Details

Particulars	Details
IPO Date	21 May 2026 to 25 May 2026
Listing Date	29 May 2026
Face Value	₹10 per share
Issue Price Band	₹132 to ₹139 per share
Lot Size	1,000 Shares
Total Issue Size	37,72,000 shares (aggregating up to ₹52.43 Cr)
Fresh Issue	33,95,000 shares (aggregating up to ₹47.19 Cr)
Offer for Sale	3,77,000 shares (aggregating up to ₹5.24 Cr)
Issue Type	Bookbuilding IPO
Listing At	NSE SME
Share Holding Pre Issue	91,80,001 shares
Share Holding Post Issue	1,25,75,001 shares
Market Maker Portion	1,89,000 shares

Bio Medica Laboratories Limited IPO Reservation

Investor Category	Shares Offered
QIB	Not less than 75% of the Net Issue
Retail	Not more than 10% of the Net Issue
NII (HNI)	Not more than 15% of the Net Issue

Bio Medica Laboratories Limited IPO Lot Size

Application	Lots	Shares	Amount
Retail (Min)	2	2,000	₹2,78,000
Retail (Max)	2	2,000	₹2,78,000
HNI (Min)	3	3,000	₹4,17,000

Bio Medica Laboratories Limited IPO Promoter Holding

Shareholding Status	Percentage
Pre-Issue	99.99%
Post-Issue	To be updated

Bio Medica Laboratories Limited IPO Valuation Overview

KPI	Value
Earnings Per Share (EPS)	₹10.67
Price/Earnings (P/E) Ratio	13.03
Return on Net Worth (RoNW)	54.41%
Net Asset Value (NAV)	₹16.05
Return on Equity	54.41%
Return on Capital Employed (ROCE)	23.22%
EBITDA Margin	47.11%
PAT Margin	30.35%
Debt to Equity Ratio	2.23

Objectives of the Proceeds

• Repayment of existing borrowings to strengthen balance sheet: ₹6.50 Cr

• Expansion of production capacity through new manufacturing facility: ₹28.50 Cr

• Funding general corporate purposes and operational requirements

Key Financials (in ₹ crore)

Particulars	30 Nov 2025	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	65.17	39.12	19.53	17.57
Revenue	28.63	38.33	15.34	16.25
Profit After Tax	8.66	9.79	2.50	0.33
Reserves and Surplus	7.94	5.55	4.84	2.34
Total Borrowings	38.17	15.01	10.49	9.61

SWOT Analysis of Bio Medica Laboratories Limited

Strengths and Opportunities	Weaknesses and Threats
Diverse injectable portfolio across human and veterinary healthcare	High debt levels may pressure financial flexibility
GMP and GLP certifications strengthen regulatory credibility	Dependence on contract manufacturing limits pricing power
Strong profitability and expanding production capabilities	Pharmaceutical regulations may increase compliance costs
Growing demand for injectable formulations supports expansion	Competitive pharma market may affect margins

IPO Strengths

• Promoters and management team possess extensive pharmaceutical expertise

• Diversified injectable product portfolio serving multiple healthcare segments

• Established client relationships through exclusive contract manufacturing model

• Strong quality assurance backed by GMP and GLP certifications

• Modern manufacturing facilities supporting scalable production growth

• Healthy profitability with strong EBITDA and PAT margins

Peer Group Comparison

Company Name	EPS (Basic)	NAV (₹ per share)	P/E (x)	RoNW (%)	P/BV Ratio
Bio Medica Laboratories Ltd.	10.67	16.05	NA	99.59	NA
Peer Group
Zenotech Laboratories Limited	0.92	15.76	NA	6.01	4.13
Shukra Pharmaceuticals Limited	0.22	1.43	47.57	15.90	20.00

Infographic Content

Bio Medica Laboratories Limited IPO Highlights

Bio Medica Laboratories Limited manufactures pharmaceutical injectables for human and veterinary healthcare, offering diversified products through a contract manufacturing model supported by certified facilities.

• Offer Size: ₹52.43 Crores (Fresh issue ₹47.19 Crores; OFS ₹5.24 Crores)

• Purpose: Funds will be used for loan repayment and production capacity expansion

• Financials (FY March 2025): Revenue: ₹38.33 crore PAT: ₹9.79 crore; EPS: ₹10.67

• Listing: SME IPO on NSE